In vivo p53 response and immune reaction underlie highly effective low-dose radiotherapy in follicular lymphoma.

Very low-dose irradiation (2 x 2 Gy) is a new, effective, and safe local treatment for follicular lymphoma. To understand the biologic mechanisms of this extremely effective response, we compared by microarray the gene-expression profile of patients' biopsies taken before and after radiation. In all patients, a major and consistent induction of p53 target genes was seen. p53 targets involved in cell-cycle arrest and apoptosis showed the same mode of regulation, indicating that, in vivo, both are activated simultaneously. p53 up-regulation and p53-mediated proliferation arrest and apoptosis were substantiated using immunohistochemistry, with activation of both the intrinsic and the extrinsic apoptotic pathways. The other induced genes revealed a whole set of biologically meaningful genes related to macrophage activation and TH1 immune response. Immunohistochemical analysis suggested a specific activation or differentiation of resident macrophages by apoptotic cells. These biologic insights are important arguments to advocate the use of low-dose radiotherapy as an effective palliative treatment for follicular lymphoma. Moreover, this study is the first in vivo report of the radiation-induced p53 apoptotic response in patients and suggests that this apoptotic response is not immunologically silent.

[1]  H. Wallerand,et al.  FGFR3 and TP53 gene mutations define two distinct pathways in urothelial cell carcinoma of the bladder. , 2003, Cancer research.

[2]  John Quackenbush,et al.  Genesis: cluster analysis of microarray data , 2002, Bioinform..

[3]  Teresa Palomero,et al.  Suppression of apoptosis by bcl-2 overexpression in lymphoid cells of transgenic zebrafish. , 2005, Blood.

[4]  M. B. Grace,et al.  Human In vivo Radiation-Induced Biomarkers , 2004, Cancer Research.

[5]  J. Cleveland,et al.  Puma is an essential mediator of p53-dependent and -independent apoptotic pathways. , 2003, Cancer cell.

[6]  A. Hart,et al.  High response rates and lasting remissions after low-dose involved field radiotherapy in indolent lymphomas. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  Wafik S El-Deiry,et al.  P53 and radiation responses , 2003, Oncogene.

[8]  J. Schouten,et al.  Expression profiling via novel multiplex assay allows rapid assessment of gene regulation in defined signalling pathways. , 2003, Nucleic acids research.

[9]  R. Knuechel,et al.  Occurrence of chromosome 9 and p53 alterations in multifocal dysplasia and carcinoma in situ of human urinary bladder. , 2002, Cancer research.

[10]  S. Kato,et al.  Understanding the function–structure and function–mutation relationships of p53 tumor suppressor protein by high-resolution missense mutation analysis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Yudong D. He,et al.  Functional Discovery via a Compendium of Expression Profiles , 2000, Cell.

[12]  T. Taniguchi,et al.  Noxa, a BH3-only member of the Bcl-2 family and candidate mediator of p53-induced apoptosis. , 2000, Science.

[13]  H. Bartelink,et al.  In vivo imaging of radiation-induced apoptosis in follicular lymphoma patients. , 2004, International journal of radiation oncology, biology, physics.

[14]  Shunsuke Kato,et al.  Predicting the transactivation activity of p53 missense mutants using a four‐body potential score derived from Delaunay tessellations , 2006, Human mutation.

[15]  Ash A. Alizadeh,et al.  Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. , 2004, Blood.

[16]  S. Koscielny,et al.  A high and sustained response rate in refractory or relapsing low-grade lymphoma masses after low-dose radiation: analysis of predictive parameters of response to treatment. , 2001, International journal of radiation oncology, biology, physics.

[17]  J. Connors.  Radioimmunotherapy--hot new treatment for lymphoma. , 2005, The New England journal of medicine.

[18]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[19]  C. Print,et al.  Constitutive Bcl-2 expression throughout the hematopoietic compartment affects multiple lineages and enhances progenitor cell survival. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  P. Taylor,et al.  A Hierarchical Role for Classical Pathway Complement Proteins in the Clearance of Apoptotic Cells in Vivo , 2000, The Journal of experimental medicine.

[21]  C. Harris,et al.  The IARC TP53 database: New online mutation analysis and recommendations to users , 2002, Human mutation.

[22]  D. Grainger,et al.  Apolipoprotein E Modulates Clearance of Apoptotic Bodies In Vitro and In Vivo, Resulting in a Systemic Proinflammatory State in Apolipoprotein E-Deficient Mice1 , 2004, The Journal of Immunology.

[23]  D. de Jong.  Molecular pathogenesis of follicular lymphoma: a cross talk of genetic and immunologic factors. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  Christian Buske,et al.  Treatment strategies in follicular lymphomas: current status and future perspectives. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  S. Dudoit,et al.  Normalization for cDNA microarray data: a robust composite method addressing single and multiple slide systematic variation. , 2002, Nucleic acids research.

[26]  John Calvin Reed,et al.  Tumor suppressor p53 is a direct transcriptional activator of the human bax gene , 1995, Cell.